Skip to main content
. Author manuscript; available in PMC: 2015 Feb 11.
Published in final edited form as: J Hepatol. 2013 Jul 16;59(5):999–1006. doi: 10.1016/j.jhep.2013.07.010

Fig. 4. BM-hMSCs protect MV from anti-MV neutralization.

Fig. 4

(A) The degree of in vitro MV infection by cell-free or cell-associated MV after exposure to increasing dilutions of measles-immune serum is represented as a percentage of syncytia count in the absence of anti-MV serum. (B) Timeline for decay of human measles-immune serum in SCID mice. (C) Bioluminescence imaging of viral spread in low and high anti-MV antibodies, (D) quantitated in photon counts. (E) Relative tumor burden in measles-naïve and passively immunized tumor-bearing mice treated with cell-free or cell-associated MV via intravenous injection; **p <0.01; *p <0.05. (This figure appears in colour on the web.)